Data presented this week at the American Society of Hematology’s 2018 annual meeting for a drug recently approved for the treatment of acute myeloid leukemia showed strong response rates among a ...

Genentech and AbbVie noted that Venclexta failed to help treat patients with newly diagnosed higher-risk MDS; However, this drug has already been approved for several other hematological indications.

The FINANCIAL — Roche, announced on june 11, that the United States Food and Drug Administration has approved Venclexta in combination with Rituxan for the treatment of people with chronic lymphocytic ...

After a spate of trial deaths forced AbbVie and Roche to halt trial enrollment for oncology med Venclexta in multiple myeloma, the future seemed dim for the drug’s expansion hopes in the disease. But ...

Roche received FDA approval for Venclexta in treating second-line patients with chronic lymphocytic leukemia. The FDA approval was possible thanks to the primary endpoint of progression-free survival ...

AbbVie and Roche’s Venclexta is leaving familiar territory with its latest approval, and it won’t be an easy land grab. To establish itself on its new turf, the blood cancer drug will have to duke it ...

Phase III VIALE-A study showed Venclexta/Venclyxto plus azacitidine helped people with the most common type of aggressive leukaemia in adults live longer compared to azacitidine alone Data will be ...

Dublin, July 10, 2019 (GLOBE NEWSWIRE) -- The "Venclexta" report has been added to ResearchAndMarkets.com's offering. Drug Overview Venclexta (venetoclax; AbbVie/Roche) is an inhibitor of the B-cell ...

RocheHolding AGRHHBY announced new data from the phase III MURANO study on Venclexta/Venclyxto (venetoclax) in patients with previously treated chronic lymphocytic leukemia (CLL) at the American ...

Roche Holdings AGRHHBY announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved ...

One of AbbVie’s most up-and-coming drugs faced a setback this week as the Food and Drug Administration placed a partial clinical hold on all the clinical trials testing it in a type of blood cancer.